The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1726
April 14, 2025
View Complete Issue         Table of Contents 2019 
Palopegteriparatide (Yorvipath) for Hypoparathyroidism
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Palopegteriparatide (Yorvipath) for Hypoparathyroidism
April 14, 2025 (Issue: 1726)
Palopegteriparatide (Yorvipath – Ascendis), a parathyroid hormone (PTH) 1-34 analog, has been approved by the FDA for treatment of hypoparathyroidism in adults. The parathyroid hormone analog teriparatide (Forteo, and others), which is approved...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Palopegteriparatide (Yorvipath) for Hypoparathyroidism
Article code: 1726c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.